Background
VIRUS
Fakhravac is an inactivated SARS-CoV-2 vaccine based on the SARS-CoV-2 IR-sb2-01 strain cultured in a Vero cell line. The IR-sb2-01 strain was isolated from hospitalized patients who had severe clinical illnesses. The virus was inactivated by formaldehyde and emulsified with aluminum hydroxide adjuvant to formulate the final vaccine product [The inactivated vaccines are the oldest and have been used for almost a century. They are safe and can be easily stored and shipped at 2–8 °C, making them suitable for many low-income countries and places with limited cold-storage capacity [The phase I and II trial of Fakhravac compared to the placebo was conducted in early 2021. The studies showed that it is generally safe and induces strong specific antibody responses against SARS-CoV-2 spike antigens in adults 18 years and older. Given the availability of a licensed vaccine, the use of a placebo was no longer justified [